Accesswire
30 Jun 2026, 00:00 UTC · 18w ago
MedMira Reports Third Quarter Results FY2026
Impact · against what's priced in
MedMira's progress in clinical trials and regulatory expansion is outweighed by severe liquidity risks. The company is facing a going concern warning and is currently negotiating the restructuring of all its debts, indicating a high probability of financial instability despite modest revenue growth.
- MIR−0.40
No priced-in read yet
- In context
While the company completed phase two clinical trials for its Syphilis test and grew quarterly revenue to $241,189, these gains are dwarfed by a working capital deficit of $365,147 and the fact that all debts are currently under negotiation for restructuring.
Read from the article alone
